These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38189099)

  • 1. Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism.
    Hamali HA
    Hemoglobin; 2023 Nov; 47(6):205-214. PubMed ID: 38189099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.
    Conran N; De Paula EV
    Haematologica; 2020 Oct; 105(10):2380-2390. PubMed ID: 33054078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis and sickle cell disease.
    De Franceschi L; Cappellini MD; Olivieri O
    Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular pathophysiology of sickle cell disease.
    Connes P; Renoux C; Joly P; Nader E
    Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment.
    Dobie G
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
    Whelihan MF; Lim MY; Mooberry MJ; Piegore MG; Ilich A; Wogu A; Cai J; Monroe DM; Ataga KI; Mann KG; Key NS
    J Thromb Haemost; 2016 Oct; 14(10):1941-1952. PubMed ID: 27430959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.
    Tantawy AA; Adly AA; Ismail EA; Habeeb NM; Farouk A
    Platelets; 2013; 24(8):605-14. PubMed ID: 23249216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling.
    Morrone K; Mitchell WB; Manwani D
    Semin Hematol; 2018 Apr; 55(2):68-75. PubMed ID: 30616808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercoagulability in sickle cell disease and beta-thalassemia.
    Singer ST; Ataga KI
    Curr Mol Med; 2008 Nov; 8(7):639-45. PubMed ID: 18991650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
    Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
    J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving treatment paradigms in sickle cell disease.
    Jagadeeswaran R; Rivers A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):440-446. PubMed ID: 29222291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle cell disease is associated with iron mediated hypercoagulability.
    Shah N; Welsby IJ; Fielder MA; Jacobsen WK; Nielsen VG
    J Thromb Thrombolysis; 2015 Aug; 40(2):182-5. PubMed ID: 25986992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.
    Francis RB
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):341-53. PubMed ID: 1893065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice.
    Yalamanoglu A; Dubach IL; Schulthess N; Ingoglia G; Swindle DC; Humar R; Schaer DJ; Buehler PW; Irwin DC; Vallelian F
    Front Immunol; 2021; 12():627944. PubMed ID: 33763072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology.
    Stuart MJ; Setty BN
    Pediatr Pathol Mol Med; 2001; 20(1):27-46. PubMed ID: 12673843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in sickle cell disease.
    Rees DC; Gibson JS
    Br J Haematol; 2012 Feb; 156(4):433-45. PubMed ID: 22122125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.
    Abdulmalik O; Darwish NHE; Muralidharan-Chari V; Taleb MA; Mousa SA
    Haematologica; 2022 Feb; 107(2):532-540. PubMed ID: 33567814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.